TOPLINE:

In a matched analysis involving 110 patients with transformed indolent non-Hodgkin lymphoma (TriNHL) and 391 patients with de novo large B-cell lymphoma (LBCL), CAR T-cell therapy showed superior outcomes in those with TriNHL, with higher 1-year progression-free survival (55.8% vs 31.7%) and overall survival (72.1% vs 50.7%).

METHODOLOGY:

• Researchers analyzed data from 110 patients with TriNHL and 391 patients with de novo LBCL from four centers of the French DESCAR-T registry.
• Analysis included patients treated with commercial CAR T-cell therapy from July 2018 to June 2023 after at least two previous lines of treatment.
• Diagnosis confirmation required concordant clinical history and expert pathological review from the LYMPHOPATH network.
• Transformation at the time of CAR T cells was confirmed through biopsy performed within 4 months before CAR T-cell infusion and after previous treatment.

TAKEAWAY:

• The 1-year progression-free survival rate was significantly higher in the TriNHL group at 55.8% (95% CI, 43.6-66.4) than in the de novo LBCL group at 31.7% (95% CI, 21.4-42.6; hazard ratio, 0.54; 95% CI, 0.36-0.82; P = .0034).
• Best overall response and complete response rates were higher in the TriNHL group (82.4% and 63.5%, respectively) than in the de novo LBCL group (63.5% and 50.6%, respectively).
• The 1-year overall survival was superior in the TriNHL group at 72.1% (95% CI, 59.6-81.4) than in the de novo LBCL group at 50.7% (95% CI, 38.2-62.0; P = .031).
• No significant differences were observed in toxicity profiles between the two groups.

IN PRACTICE:

“In conclusion, our matched-comparison study revealed a greater efficacy of CAR T-cell therapy, with a toxicity profile for patients with TriNHL comparable with that for patients with LBCL,” the authors of the study wrote.

SOURCE:

The study was led by Pierre Stephan, Department of Hemato-Oncology, Hôpital Saint Louis in Paris, France. It was published online in Blood Advances.

LIMITATIONS:

The study datasets are not publicly available due to proprietary considerations. All data were anonymized to protect patient privacy in accordance with applicable laws and regulations.

DISCLOSURES:

Stephan disclosed having ties with AbbVie, BeiGene, and Institut Servier. Roberta Di Blasi reported having relationships with Novartis, Kite/Gilead, Janssen, and Bristol Myers Squibb, and additional pharmaceutical companies. Additional disclosures are noted in the original article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.